A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Status:
Recruiting
Trial end date:
2027-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206
compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.